Sponsors (9)
The bill would lower out‑of‑pocket drug costs and expand access for many patients by allowing regulated imports, but it creates significant safety, administrative, and long‑term innovation tradeoffs that depend on strict enforcement and oversight.
Low- and middle-income patients (including people with chronic conditions and Medicare beneficiaries) can pay less for many prescription drugs because authorized importation from approved countries and personal imports (up to a 90‑day supply) make lower-priced equivalents available.
Patients who previously skipped or rationed medications due to cost are more likely to fill prescriptions and adhere to treatment, improving health outcomes for chronic conditions.
The program builds in multiple safety features—certification of foreign regulators/manufacturers, quality-assurance testing, English labeling, reporting, and suspension authority—which aim to protect drug quality and public health.
Patients and health systems face meaningful safety risks if enforcement is imperfect: imported products could be non‑FDA‑identical, counterfeit, diverted, or misbranded, complicating prescribing, monitoring, and patient safety.
Implementing and enforcing the importation program will raise regulatory and administrative costs for FDA/HHS, which may be borne by taxpayers or shifted to manufacturers through fees.
Pharmacies, wholesalers, and manufacturers will face increased compliance complexity (certification, biannual reporting, special labeling, tracking), adding operational burden and costs that could be passed on or limit participation.
Based on analysis of 3 sections of legislative text.
Requires HHS to allow certified foreign sellers and licensed foreign pharmacies to import certain foreign-approved prescription drugs into the U.S. within one year under a regulated program.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.
Introduced May 1, 2025 by Janice D. Schakowsky · Last progress May 1, 2025
Requires the Department of Health and Human Services to issue rules within one year allowing regulated importation of certain lower-cost, foreign-approved prescription drugs by certified foreign sellers, licensed foreign pharmacies, wholesale distributors, pharmacies, and individuals. Establishes definitions, eligibility criteria, and a certification/listing system for foreign sellers and importers, and narrows which drugs may be imported (including many complex products for importers) while excluding controlled substances and specified other categories. Sets a mandatory deadline for HHS rulemaking, reframes importation law around "safe and affordable" imports, and expresses congressional findings that high U.S. drug prices and mature foreign regulatory systems justify a permitted, supervised import pathway to lower prices for patients.